Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥ 50 Years: Final 96-Week Results of the NEAT022 Study
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥ 50 Years: Final 96-Week Results of the NEAT022 Study
复制标题
DOI：
10.1093/cid/ciy505
复制
发表时间：
2019-02-15
影响因子：
11.8
通讯作者：
Johnston, Sarah
中科院分区：
文献类型：
--
作者：
Gatell, Jose M.;Assoumou, Lambert;Johnston, Sarah
背景。从利托那韦增强的蛋白酶抑制剂（PI/r）为基础的方案立即或延迟切换到多替替韦（DTG）为基础的方案可能改善血脂。欧洲艾滋病治疗网络022研究（NEAT022）是一项欧洲开放标签随机试验。年龄b> = 50岁或Framingham评分b>10%的人类免疫缺陷病毒（HIV）感染成人，如果HIV RNA为
Background. Both immediate and deferred switching from a ritonavir-boosted protease inhibitor (PI/r)-based regimen to a dolutegravir (DTG)-based regimen may improve lipid profile.Methods. European Network for AIDS Treatment 022 Study (NEAT022) is a European, open-label, randomized trial. Human immunodeficiency virus (HIV)-infected adults aged >= 50 years or with a Framingham score > 10% were eligible if HIV RNA was